Anti-Human S1P Recombinant Antibody (TAB-H64) (CAT#: TAB-H64)

Campanella, Rolando, et al. "Tumor-educated platelets and angiogenesis in glioblastoma: another brick in the wall for novel prognostic and targetable biomarkers, changing the vision from a localized tumor to a systemic pathology." Cells 9.2 (2020): 294. https://doi.org/10.3390/cells9020294

This research investigates the role of platelets (PLTs) in glioblastoma (GBM) microenvironment modulation through a process termed "tumor education." The study demonstrates that PLTs from GBM patients exhibit a more activated state compared to those from healthy donors, with higher expression of P-selectin even under basal conditions. These tumor-educated platelets (TEPs) carry and release significantly higher levels of pro-angiogenic and oncogenic factors including sphingosine-1-phosphate (S1P), vascular endothelial growth factor (VEGF), von Willebrand Factor (VWF), and their associated receptors. Functional assays revealed that GBM patient PLT-releasate significantly enhanced angiogenic activity in GBM endothelial cells, promoting the formation of more complex vascular networks compared to healthy donor PLT-releasate.
Creative Biolabs provided Sonepcizumab, a monoclonal antibody that specifically recognizes S1P, which played a crucial role in detecting and quantifying this bioactive lipid both within platelets and in platelet releasate. This antibody enabled the researchers to demonstrate the enrichment of S1P in GBM platelets and establish its role in the pro-angiogenic effects observed. By facilitating the visualization and measurement of S1P, Creative Biolabs' reagent helped establish the concept of platelets as functional circulating carriers of oncogenic signals, advancing our understanding of GBM as a systemic pathology rather than merely a localized tumor.

Park, Ji-Hye, et al. "Synthesis and Characterization of an Amino-oxy-modified Sphingosine-1-Phosphate Derivative that Can Replace Thiolated-S1P in Competitive ELSIA." Bulletin of the Korean Chemical Society 41.4 (2020): 460-467. https://doi.org/10.1002/bkcs.11994

This research focuses on the synthesis and characterization of a novel amino-oxy-modified sphingosine-1-phosphate (S1P) derivative that can effectively replace thiolated-S1P in competitive enzyme-linked immunosorbent assays (ELISA). S1P is an important signaling molecule that has emerged as a valuable biomarker for early diagnosis of conditions like osteoporosis and cancer. The researchers successfully synthesized the amino-oxy-modified S1P, which offers significant advantages over thiolated-S1P, including better stability against oxidation, improved water solubility, and the ability to be directly immobilized on microtiter plates without requiring additional linkers. Direct ELISA testing confirmed that the new derivative effectively binds to anti-S1P antibodies and provides comparable results to conventional thiolated-S1P references.
Creative Biolabs provided the anti-human S1P antibody (biotin conjugated) that was essential for validating the functionality of the newly synthesized amino-oxy-modified S1P in direct ELISA assays. This antibody enabled the researchers to demonstrate that the novel S1P derivative could be recognized by commercially available S1P antibodies, confirming its potential as a viable replacement for thiolated-S1P in diagnostic applications. The company's high-quality reagents played a crucial role in establishing that the amino-oxy-modified S1P could be effectively immobilized on maleic anhydride-activated plates and used for quantitative S1P detection, potentially simplifying the manufacturing process of S1P-based diagnostic kits.